NeuroPace (NPCE) announced that it has filed a premarket approval supplement, or PMA-S, application to the FDA seeking to expand the labeled indication for its RNS System to include patients with antiseizure-medication resistant idiopathic generalized epilepsy with generalized tonic-clonic seizures.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NeuroPace price target raised to $22 from $18 at UBS
- NeuroPace price target raised to $20 from $18 at JPMorgan
- Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
- NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting
- NeuroPace announces Medicare reimbursement increases for RNS System